I'll chime in on that note. Just sporadically reviewing a few posts here and there on a couple different sites. Clear to me that some are doing their best to discourage someone from looking closer at Cellceutix.
Perception can take ones money in a heart beat. Is it the company's job to fix perception when it gets out of whack? To an extent perhaps. But if the company is proving itself by moving forward and straightening out previous mistakes does that help clean the slate? To an extent perhaps. Rehashing the same things over and over on a message board, that's certainly a way to get something fixed right? Squeaky wheel gets the grease mode of thinking? Perhaps not. But many vent anyway. Or purposely post their rants to keep others away.
Anyway, about a deal on prurisol, 1st I'd say it depends on the "who", and then on the "what". For example, a pharma company from China makes a deal for a mid stage bio entering phase III giving the company $15M up front with another say $350M in milestone payments over a 3 year span (or however long P3 is likely to take) really is a drop in the bucket. This kind of deal would do squat for CTIX to be able to move anything forward without a significant raise along with it.
One thing Cellceutix has done is taken the time to do smaller studies to better target their drugs. With these results brings better opportunity to present for a better deal. We need that $15M to be closer to $100M. I cringe when I see companies realign their shelf registration to astronomical #'s like a 250M shelf. It happens all the time though and then the dilution is almost endless, but that's what they need to do to survive as a start up - mid stage pre-revenue.
Prurisol topline data, will this be their ticket to land a real institutional?
I have my shares. It's a shame some can't keep emotion out of the picture and use these boards continuously for their BS.
If there is a partnership deal, it will involve an up-front payment to CTIX. To claim that the stock price won't go up until there is a royalty stream coming in is just utter BS. The absurd market cap of about 150 million for a company with 3 different drugs in 5 clinical trials has been a product of a concerted effort by short sellers. It will be impossible for them to keep the price down when good clinical trial news comes out.